Leukemia, Lymphocytic, Acute, L2
Leukemia, Lymphocytic, Acute, L2
Explore linked clinical trials. Standard reference: MESH:M00238123 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L2, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT07387926 | |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L1, Leukemia, Lymphocytic, Acute, L2, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-08-26 | NCT05495035 | |
| A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | Hemic and Lymphatic Diseases, Leukemia, Lymphocytic, Acute, L2, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-04-30 | NCT06051409 |